scholarly journals Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin

2020 ◽  
Vol 142 (6) ◽  
pp. 637-640 ◽  
Author(s):  
Anne‐Kathrine Ryltoft ◽  
Ali Al‐Zuhairy ◽  
Søren H. Sindrup ◽  
Henning Andersen ◽  
Lars K. Markvardsen
Keyword(s):  
Quality Of Life ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Demyelinating Polyneuropathy ◽  
Subcutaneous Immunoglobulin ◽  
Inflammatory Demyelinating Polyneuropathy

scholarly journals Chronic inflammatory demyelinating polyneuropathy: quality of life, sociodemographic profile and physical complaints

2014 ◽  
Vol 72 (3) ◽  
pp. 179-183 ◽  
Author(s):  
Patricia Leila dos Santos ◽  
Graziela A. Nogueira de Almeida-Ribeiro ◽  
Daniele Miguel Daoud Silva ◽  
Wilson Marques Junior ◽  
Amilton Antunes Barreira
Keyword(s):  
Quality Of Life ◽  
Mental State ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Short Form ◽  
Demyelinating Polyneuropathy ◽  
Functional Impairments ◽  
Health States ◽  
Inflammatory Demyelinating Polyneuropathy ◽  
Sociodemographic Profile

Whereas an evaluation of quality of life and possible impacts on the mental state of a patient may help to evaluate the evolution of chronic inflammatory demyelinating polyneuropathy (CIDP), the aim of this study was to study the psychological profile of patients, and evaluate quality of life associated with the disease. Method 41 patients were evaluated using a Mini-Mental State Examination (MMSE) and a Short-Form Health Survey (SF-36). Results The mean age of the patients was 50.6 years, 63.4% men. Of the participants, 65.9% had other health problems, 39% reported needing help with activities of daily living, 49% slept less than 8 hours per night, and 34.1% complained of some memory deficit. The average MMSE score was 26. Impairment of functional capacity and pain were the more important altered health states. Conclusion CIDP has important social and economic impacts, owing to functional impairments that can lead to professional and personal limitations.

Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy

US Neurology ◽  
2017 ◽  
Vol 13 (01) ◽  
pp. 26 ◽  
Author(s):  
Jeffrey A Allen ◽  
Deborah F Gelinas ◽  
Richard A Lewis ◽  
Richard J Nowak ◽  
Gil I Wolfe ◽  
...  
Keyword(s):  
Outcome Measures ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Unmet Need ◽  
Daily Practice ◽  
Demyelinating Polyneuropathy ◽  
Disability Score ◽  
Sum Score ◽  
Inflammatory Neuropathy ◽  
Inflammatory Demyelinating Polyneuropathy

The challenges encountered during the assessment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) are many. Ideally, CIDP outcome measures capture impairments in disability, strength, and sensory dysfunction, and quality of life (QoL). A number of outcome measures have been validated for this purpose. Disability outcomes include the adjusted inflammatory neuropathy cause and treatment (INCAT) disability score, INCAT overall disability sum score (ODSS), and overall neuropathy limitations scale (ONLS). A more sensitive disability score, the inflammatory Rasch-built overall disability scale (I-RODS), has also been validated for use in clinical trials and may better capture clinically meaningful changes in those with CIDP. Strength and sensory impairment can be assessed in a number of ways, including the INCAT sensory subscore (ISS), Medical Research Council sum score, and Martin vigorimeter or Jamar dynamometer grip strength. However, the feasibility of applying and interpreting these measures during routine daily practice has been questioned. Furthermore, these outcome measures may not reflect other factors that can impair QoL in those affected by CIDP, such as pain and fatigue. A valid, reliable, and responsive composite measure that addresses all aspects of impairment faced by patients with CIDP remains an unmet need in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document